Innate Pharma SA (OTCMKTS:IPHYF) Short Interest Up 746.2% in September

Key Points

• Innate Pharma SA experienced a dramatic increase in short interest of 746.2% in September, rising from 1,300 shares to 11,000 shares.
• The company's current price is around $2.00, with a fifty-two week range between $1.31 and $2.06.
• Innate Pharma is actively developing multiple immunotherapies for cancer, including candidates in various stages of clinical trials targeting different types of cancer.

Innate Pharma SA (OTCMKTS:IPHYF - ) was the recipient of a large growth in short interest in the month of September. As of September 15th, there was short interest totaling 11,000 shares, a growth of 746.2% from the August 31st total of 1,300 shares. Based on an average trading volume of 14,400 shares, the days-to-cover ratio is presently 0.8 days. Based on an average trading volume of 14,400 shares, the days-to-cover ratio is presently 0.8 days.

Innate Pharma Price Performance

IPHYF opened at $2.00 on Wednesday. Innate Pharma has a fifty-two week low of $1.31 and a fifty-two week high of $2.06. The business has a 50-day moving average of $1.83 and a 200-day moving average of $1.78.

About Innate Pharma

Innate Pharma SA, a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.